| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909274 | Leukemia Research | 2012 | 5 Pages |
Abstract
R-dex appears to be an active and feasible treatment for relapsed/refractory CLL. Infectious toxicity remains an important issue. Further investigation of this regimen in larger studies appears fully warranted.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
LukáÅ¡ Smolej, Michael Doubek, Anna Panovská, Martin Å imkoviÄ, Yvona Brychtová, David Belada, Monika MotyÄková, JiÅà Mayer,